Please select the option that best describes you:
When do you use high-dose IL-2 for metastatic renal cell carcinoma?
Are there circumstances when you would choose IL-2 over checkpoint inhibitor trials or TKIs for fit patients? How should IL-2 be sequenced with these other options?
Answer from: Medical Oncologist at Academic Institution
In general, as an academic investigator, I always prefer clinical trials over standard of care. However, most of the front line registration trials in mRCC with immunotherapy have recently completed accrual, with results currently awaited. I continue to offer the option of high dose Interleukin-2 (H...
Sign in or Register to read more